R

RenovoRx
D

RNXT

1.16000
USD
0.08
(7.41%)
Market Closed
Volume
7,624
EPS
0
Div Yield
0
P/E
-2
Market Cap
27,824,582
OverviewSignalsIdeasNews
Related Instruments
    AAPL
    -3.610
    (-1.63%)
    218.370 USD
    AMD
    -11.890
    (-8.23%)
    132.580 USD
    AMZN
    -3.000
    (-1.60%)
    183.990 USD
    CRM
    -5.730
    (-2.21%)
    253.060 USD
    GOOGL
    -0.710
    (-0.41%)
    170.760 USD
    MSFT
    -1.14
    (-0.27%)
    417.07 USD
    NFLX
    -3.53
    (-0.56%)
    624.46 USD
    NVDA
    -7.750
    (-6.62%)
    109.380 USD
    SHOP
    -3.080
    (-5.03%)
    58.150 USD
    TSLA
    -15.150
    (-6.53%)
    216.890 USD
    More
News

Title: RenovoRx

Sector: Healthcare
Industry: Biotechnology
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.